Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Sydney Thai, Joe Zhuo, Yichen Zhong, Qian Xia, Xiu Chen, Ying Bao, Devender Dhanda, Lawshia Priya & Jashin J. Wu. (2023) Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies. Journal of Dermatological Treatment 34:1.
Read now
Read now
Articles from other publishers (8)
Ashis K. Das, Eunice Chang, Caleb Paydar, Michael S. Broder, Kate K. Orroth & Myriam Cordey. (2023) Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic. Dermatology and Therapy 13:9, pages 1973-1984.
Crossref
Crossref
Sydney Thai, Sophie Barlow, James Lucas, James Piercy, Yichen Zhong, Joe Zhuo & Jashin J. Wu. (2023) Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey. Dermatology and Therapy 13:6, pages 1289-1303.
Crossref
Crossref
Philipp Sewerin, Kathrin Borchert, Dominic Meise, Matthias Schneider & Jörg Mahlich. (2022)
Health Resource Utilization and Associated Health Care Costs of Biologic
Disease‐Modifying
Antirheumatic Drugs in German Patients With Psoriatic Arthritis
. Arthritis Care & Research 74:9, pages 1435-1443.
Crossref
Crossref
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb & Alan Kivitz. (2022) Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Annals of the Rheumatic Diseases 81:3, pages 351-358.
Crossref
Crossref
Jessica A. Walsh, Qian Cai, Iris Lin, Christopher D. Pericone & Soumya D. Chakravarty. (2021) Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study. Advances in Therapy 38:5, pages 2353-2364.
Crossref
Crossref
Thomas Graier, Wolfgang Weger, Paul-Gunther Sator, Wolfgang Salmhofer, Barbara Gruber, Constanze Jonak, Claudia Kölli, Martina Schütz-Bergmayr, Igor Vujic, Gudrun Ratzinger, Nina Häring, Clemens Painsi, Knut Prillinger, Alexander Mlynek, Hans Skvara, Hannes Trattner, Adrian Tanew, Roland Lichem, Christina Ellersdorfer, Franz Legat, Alexandra Gruber-Wackernagel, Angelika Hofer, Erich Schmiedberger, Wolfram Hoetzenecker, Robert Müllegger, Werner Saxinger, Franz Quehenberger & Peter Wolf. (2021) Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis. JAAD International 2, pages 62-75.
Crossref
Crossref
Martin Bergman, Pankaj Patel, Naijun Chen, Yonghua Jing & Christopher D. Saffore. (2020) Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatology and Therapy 8:1, pages 109-118.
Crossref
Crossref
Rituparna BhattacharyaKatie HerrenInsiya PoonawallaSuvapun BunniranAndrea BloomfieldPhil Schwab. (2020) Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1246-1256.
Crossref
Crossref